These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


149 related items for PubMed ID: 7586933

  • 1. In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (+/-)-fluvastatin.
    Transon C, Leemann T, Vogt N, Dayer P.
    Clin Pharmacol Ther; 1995 Oct; 58(4):412-7. PubMed ID: 7586933
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin: effect on human cytochrome P-450 and implications for metabolic drug interactions.
    Fischer V, Johanson L, Heitz F, Tullman R, Graham E, Baldeck JP, Robinson WT.
    Drug Metab Dispos; 1999 Mar; 27(3):410-6. PubMed ID: 10064574
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Effect of clopidogrel on the steady-state pharmacokinetics of fluvastatin.
    Ayalasomayajula SP, Vaidyanathan S, Kemp C, Prasad P, Balch A, Dole WP.
    J Clin Pharmacol; 2007 May; 47(5):613-9. PubMed ID: 17442686
    [Abstract] [Full Text] [Related]

  • 8. Substrate-dependent effect of acetonitrile on human liver microsomal cytochrome P450 2C9 (CYP2C9) activity.
    Tang C, Shou M, Rodrigues AD.
    Drug Metab Dispos; 2000 May; 28(5):567-72. PubMed ID: 10772636
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. An evaluation of the in vitro metabolism data for predicting the clearance and drug-drug interaction potential of CYP2C9 substrates.
    Andersson TB, Bredberg E, Ericsson H, Sjöberg H.
    Drug Metab Dispos; 2004 Jul; 32(7):715-21. PubMed ID: 15205386
    [Abstract] [Full Text] [Related]

  • 12. Clinical pharmacokinetics of fluvastatin.
    Scripture CD, Pieper JA.
    Clin Pharmacokinet; 2001 Jul; 40(4):263-81. PubMed ID: 11368292
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The effects of fluvastatin, a CYP2C9 inhibitor, on losartan pharmacokinetics in healthy volunteers.
    Meadowcroft AM, Williamson KM, Patterson JH, Hinderliter AL, Pieper JA.
    J Clin Pharmacol; 1999 Apr; 39(4):418-24. PubMed ID: 10197301
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Lack of pharmacokinetic interaction between fluvastatin and green tea in healthy volunteers.
    Misaka S, Abe O, Sato H, Ono T, Shikama Y, Onoue S, Yabe H, Kimura J.
    Eur J Clin Pharmacol; 2018 May; 74(5):601-609. PubMed ID: 29368187
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Effect of atorvastatin and fluvastatin on the metabolism of midazolam by cytochrome P450 in vitro.
    Mc Donnell CG, Shorten G, Van Pelt FN.
    Anaesthesia; 2005 Aug; 60(8):747-53. PubMed ID: 16029222
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 8.